Authors´ conclusions: there is a low risk of intussusception in the 3-7 days following vaccination with the first dose of the pentavalent rotavirus vaccine: RV5. Although this risk does not outweigh the benefits, family members should be advised of the alarm signs in order to proceed to early diagnosis.
Reviewers´ commentary: the RV5 vaccine postmarketing studies warn of a rare side effect: intussusception 3 to 14 days after the first dose. Each country should decide if the use of the vaccine is justified for your environment, having in mind the risk -no measurable, given the type of study design-, and the demonstrated benefits (the protective effect against severe gastroenteritis). This decision should be especially individualized in the subgroups most vulnerable to suffering adverse reactions (e.g.: ex-preterm infants), or in those less likely to develop severe forms of acute gastroenteritis (breast milk fed). In any case, the family should be informed of the risk they are assuming.